Targeting lipid metabolism to overcome EMT-associated drug resistance via integrin β 3/FAK pathway and tumor-associated macrophage repolarization using legumain-activatable delivery
Conclusion: This study provides a promising simvastatin-based nanomedicine strategy targeting cholesterol metabolism to reverse EMT and repolarize TAM to treat drug-resistant cancer. The elucidation of the molecular pathways (cholesterol/lipid raft/integrin β3/FAK and cholesterol-associated LXR/ABCA1 regulation) for anti-EMT and the new application of simvastatin should be of clinical significance.
Source: Theranostics - Category: Molecular Biology Authors: Hongyue Jin, Yang He, Pengfei Zhao, Ying Hu, Jin Tao, Jiang Chen, Yongzhuo Huang Tags: Research Paper Source Type: research
More News: Cancer | Cancer & Oncology | Chemotherapy | Cholesterol | Epithelial Cancer | Molecular Biology | Nanotechnology | Simvastatin | Statin Therapy | Study | Zocor